

TYPE JUL 27 2001 PATENT & TRADEMARK OFFICE

03CO
Box seq

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/759,484	
	Filing Date	01/12/01	
	First Named Inventor	Perritti, M. et al.	
	Group Art Unit	TBA	
	Examiner Name	TBA	
Total Number of Pages in This Submission	9	Attorney Docket Number	1493-131 US


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> See Remarks section for items
Remarks		Diskette containing sequence listing and hard copy of same Notice to Comply with Requirements for patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures from PTO.


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Timothy X. Gibson Reg. No. 40,618 for Mathews, Collins, Shepherd & Gould, P.A.		
Signature			
Date	07/23/01		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text" value="07/23/01"/>			
Typed or printed name	Valerie Balfour		
Signature		Date	07/23/01

Burden Hour Statement: This form is estimated to take 0.2/hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



1493-131 US

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Assistant Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, D.C. 20231 on July 23, 2001.


Valerie Balfour

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Perritti, et al.

Serial No. 09/759,484

Filed: January 12, 2001

For: ANTI-INFLAMMATORY
COMPOUNDS

Group Art Unit: TBA
Examiner: TBA

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

SIR:

**Response to Notice to Comply with
Requirements for Patent Applications
Containing Nucleotide Sequence and/or
Amino Acid Sequence Disclosures**


A Response is hereby made to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (a copy of which is enclosed) as required under 37 CFR 1.821-1.825. Enclosed is paper and a diskette containing a computer-readable form of the sequence listing as required under 37 CFR 1.821-1.825. et. seq.

It is hereby requested that these submissions be entered into the application.

No fee is believed due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Mathews, Collins, Shepherd & Gould, P.A. Deposit Account No. 13-2165; a duplicate of this sheet is enclosed.

Respectfully submitted,

Date: 7-23-01


Timothy X. Gibson
Reg. No. 40,618

Mathews, Collins, Shepherd & Gould, P.A.
100 Thanet Circle, Suite 306
Princeton, New Jersey 08540

Phone (609) 924-8555
Fax (609) 924-3036

09759404-07E704



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/759,484	01/12/2001	Mauro Perritti	1493-13 US

CONFIRMATION NO. 1744

FORMALITIES LETTER



OC000000006152301

Mathews, Collins, Shepherd & Gould, P.A.
Suite 306
100 Thanet Circle
Princeton, NJ 08540

Date Mailed: 06/06/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

2/24

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

0075940701